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CONCLUSIONS. There were significant improvements in health-related quality of life (HRQL) associated with Transitional Care and Individuals with congestive heart failure (CHF) are one of the fastest growing and challenging complex health populations requiring care in both the hospital and community sectors. The incidence of CHF increases dramatically with age, and there is a 50% mortality after 5 years.1'2 CHF is reported to be the only cardiovascular condition that is increasing in incidence, prevalence, morbidity, and mortality.2-5 Heart failure may be an even greater public health problem than the statistics reveal. Estimates rely on ICD codes for primary and secondary diagnosis, and these have been reported to exclude one third of patients with clinical evidence of acute CHF. 6 For individuals and families dealing with heart failure, the condition poses significant challenges in terms of day-to-day living and the burden of care. Frequent hospital admissions are common.7'8 There is a fragile balance between coping with this long-term condition at home and the exacerbations, often life-threatening, which require hospitalization. Considering the illness trajectory of individuals with heart failure and the therapeutic limits of drug therapies, the effectiveness of nonpharmaceutical, adjunctive interventions has become a clinical and research priority. These interventions include enhancing self-management and symptom control through knowledge, diet, rest and exercise, and proactive symptom monitoring. The former Agency for Health Care Policy and Research (AHCPR) guidelines4 for CHF, for example, make eight specific recommendations related to hospital discharge and counseling, and selfmanagement. Professional bodies agree that effective management of this condition requires collaborative, proactive vigilance of medical therapies by health care providers and active support for selfmanagement before and after hospitalizations.4'9 Recommendations about incorporating a comprehensive approach across sectors of care (hospital, ambulatory, and home care) have followed closely on the interational efforts with clinical practice guidelines about heart failure.9 Recent randomized trials7,10-12 have begun to rigorously evaluate the effectiveness of delivery models emphasizing supportive care for self-management (telephone outreach, patient education and information), and indiless use of emergency rooms. A key aspect for improvements is through the reinforcement of a practitioner's normal ability to bridge these gaps. In the case of heart failure, our premise was that adding a new provider might not be the most effective, feasible, or efficient solution. Could the gap be bridged another way? Rather, by focusing on the activities of usual providers, and the structure and process of transition from hospital-to-home, could continuity with support for self-management be enhanced to improve patient outcomes and reduce health service utilization?
We conducted a prospective, randomized trial to evaluate whether the use of usual providers, and a reorganization of discharge planning and transition care with improved intersector linkages between nurses, could improve quality of life and health services utilization for individuals admitted to hospital with heart failure. It was hypothesized that the enhanced transition process would improve quality of life and reduce emergency room visits and hospital admissions for individuals discharged from hospital with heart failure.
Materials and Methods

Study Patients and Setting
All individuals admitted to two general medical units of a large urban teaching hospital in Ottawa, Ontario, Canada, with a diagnosis of congestive heart failure, were screened for the study. 
Randomization
Using a computer-generated schedule, consenting patients were randomized by the research coordinator, within 24 hours of hospital admission, to receive either Usual Care or Transitional Care. Prepackaged, consecutively numbered, sealed, opaque envelopes containing the group allocation were prepared for each nursing unit and administered from the research office. Neither the patients, nor the members of the study team, were aware of treatment assignment until after randomization. During hospitalization, the staff physicians established the medical regimen. Other usual providers included hospital and community primary nurses and the home care coordinators. Usual discharge procedures are described and compared with Transitional Care in Table 1 . With respect to usual discharge planning and postdischarge care, patients in the control group received optimal usual care in that the timing and number of home nurse visits were scheduled to match those received by Transitional Care group. The similar number of home visiting and provider contacts during the intervention period (2 weeks after hospital discharge) controlled for the effect of attention alone.
On admission to hospital, the research coordinator flagged the patient's chart as a signal to the patient's primary nurse to follow a checklist of activities for Transitional Care. The protocol was implemented from admission to 2 weeks after hospital discharge, after which the patient received usual care by community nurses while on home care. During the pilot study for this trial, the 10 to 14 days after hospital discharge was identified as the critical 'settling in' period after hospitalization. It was also a typical length of stay for home care follow-up after hospitalization. Eleven individuals were readmitted to hospital within 2 weeks of discharge (the intervention period). Timing for outcome measures then began on the second discharge and followed for 3 months.
Usual Care and the Transitional Care Intervention
Usual care for hospital-to-home transfer involves completion of medical history, nursing assessment form, and, in ideal circumstances within 24 hours of hospital admission, a multidisciplinary discharge plan. Weekly discharge planning meetings further identify patient needs. A regional home care co-coordinator consults with the hospital team as required and may meet directly with patients and families. Immediately before discharge, a physician completes a referral for home care, and necessary services and supplies are communicated to the home nursing agency. Usual home nursing care for CHF patients includes assessment and monitoring, health teaching, provision of direct care, eg, administration of medications, and managing equipment and treatments.
Patients in the Transitional Care (TC) arm received the standard discharge planning and care, plus a comprehensive program, adding supports to improve the transfer from hospital to home. To develop this program, hospital and community nurses met to focus on the 'outreach' from the hospital and 'in-reach'from the community during the transition. An intersectoral continuity of care framework19 guided their efforts in identifying gaps to specifically address 3 major aspects of a hospital-to-home transition: (1) Hospital and home care clinical nursing staff delivered care to both the Usual Care and the TC groups. Two nurse research coordinators, reporting through the Clinical Epidemiology Unit, managed this trial. They were not connected in any way to either the hospital or home care departments, and wore research ID badges to avoid being mistaken for clinical nursing staff. The coordinators screened and recruited the participants and collected baseline data. On admission, profile information was collected through chart audit using standardized forms for demographic and circumstance of living data and clinical data, including previous admissions, comorbidities, and severity of medical problems from admitting notes and history. Outcome data were collected within 24 hours of discharge (T1) and at two (T2), six (T3), and 12 weeks (T4) after hospital discharge. Appointments in the home were made independent of scheduled home care visits. Patients had the option to complete the forms themselves or partake in a structured interview with the research staff. The majority (>90%) preferred the structured interview.
Analysis
The sample size was based on detecting a clinically important difference in the Minnesota Living with Heart Failure Questionnaire. From changes in function and well-being experienced by patients in placebo controlled angiotensin converting enzyme inhibitor (ACE) trials, the developers of the scale determined that 5 points (4.8%) was the minimally clinically important difference (MCID) in score.23,25,30,31 With the probability of a type I error set at 0.05 and power of 80%, 50 patients per group were required to detect a 5-point difference in the MLHFQ score, assuming a SD of 9 for the change scores (personal communication, Thomas Rector, May 1996). Allowing for 30% withdrawal because of death or study dropout, and an additional 20% for sufficient statistical power to perform physical and emotional dimension subscale analysis, 75 participants per group were required.
Descriptive statistics (means, SD, proportions) were used to determine the characteristics of those completing the trial and the study dropouts. The success of randomization was determined by comparing the intervention group with the Usual Care group profile on demographic and clinical variables at baseline (Tl) using x2 test for categorical variables or the Student t test for continuous variables.
Participants in the study were followed for 12 weeks after hospital discharge. All those completing outcome measures, whether they received the intervention, were included in the analyses to conduct an intention-to-treat/completer analysis.
The primary analysis tested the mean difference in the condition-specific quality of life outcome (MLHFQ) between baseline and 6 and 12 weeks postdischarge with the 2 study groups. Mean differences were compared using the independent t test with either the pooled or separate variance estimate as appropriate. To assess trends over time, a two-way analysis of variance (ANOVA) compared each outcome across two factors: the cohort (usual care or TC) and time (baseline and after hospital discharge repeated measures). The clinical importance was assessed using a minimally clinical importance difference (MCID). The MCID was defined as a 5-point or greater change in the total MLHFQ score and 5% change in the physical and emotional dimension scores (2 points on the physical dimension score, 1.25 points on the emotional dimension score). The scores are calculated in whole numbers on a 5-point scale; therefore, the MCID for the emotional dimension was rounded upward to 2 points. Thus, a change of ? 2 points was classified as 'no change'. This had the conservative effect of requiring a 12% deterioration in score to be in the 'worse' category.
Results
Baseline Characteristics
Trial Participants. In the 18 months of study (June 1996 -January 1998), 483 patients with heart failure were admitted to the two study units. Once screened, 212 of these admissions were deemed eligible, and 200 individuals consented to participate (5.6% refusal). Reasons for patient ineligibility included: coming from or being discharged to a long-term care facility (n = 104, 38%); living outside the catchment area for home care (n = 63, 23%); too ill, or deceased, shortly after admission (n = 40, 15%); first language other than French or English (n = 33, 12%); being discharged <24 hours (n = 16, 6%); diagnosis changed (n = 8, 3%); other (n = 7, 3%). The baseline profile (TI) of the study population after randomization (n = 192) was one of a fairly elderly group. Less than 7% were under 60 years of age and the mean age was 76 years (median 77 years, range 33-93 years). Most participants (91%) were retired or on disability pension, and nearly half lived alone. Most (76%) had at least some high school education. Nearly 80% had NYHA Functional Class4 III or IV as assessed by the nurse research coordinator on admission. On average, individuals took six prescription medications daily ( Table 2) .
Comparability of Experimental and Control Participants.
Profiles of those completing the study to 12 weeks (n = 157) and those who did not complete (n = 35) were similar, with no statistically significant differences on any of the demographic or clinical variables. A comparison of the clinical, social and demographic characteristics of the Usual Care and TC groups revealed well-balanced groups with no statistically significant differences in the baseline characteristics between the experimental and control participants (Table 2) . A further comparison was made with these characteristics and the 157 participants who completed the study, and again, no differences were found.
Quality of Life
With the primary outcome measure, the ML-HFQ a lower score indicates less disability from symptoms (range 0-105). The trend over time with the total MLHFQ score is one of continued improvement for the TC group (Fig. 1) . The effect of hospitalization and the intervention are intertwined at 2 weeks (T2). As expected, quality of life for participants in both groups improved at the 2-week point (T2) as a hospital admission indicates a pressing need for medical intervention. Alleviation of the exacerbation precipitating the hospitalization would be expected to result in improvements, regardless of the group assignment. While those receiving usual care showed no further improvement at 6 and 12 weeks, the TC group showed both clinical and statistically significant improvements in their reported healthrelated quality of life (HRQL) ( Table 3 ). The patter was similar with the MLHFQ physical dimension score (Table 3) . With the emotional dimension of the MLHFQ TC group the scores improved significantly at T3 compared with baseline and were sustained at 12 weeks, compared with Usual Care participants who had no improvement in this score at 6 or 12 weeks.
Clinical Importance of the Quality of Life Improvements
Relative changes in score between baseline and T4 (T1-T4, divided by T1) provide an indication of the clinical importance of the change in MLHFQ scores (Table 3) . For instance, in the total MLHFQ scores at 12 weeks, the improvement from baseline for the TC group was 43% compared with 14% for Usual Care group. With the physical dimension, the TC group improved 42% from baseline compared with 9% for Usual Care participants. Although having only borderline statistical significance, the relative change in score was greatest with the MLHFQ emotional dimension where improvement was 36% for the TC group, compared with less than 1% with Usual Care.
To further understand the clinical importance of the differences in MLHFQ scores, the proportion of individuals in each group with a predefined MCID score at 6 and 12 weeks were tabulated. Classifying scores into 'worse, 'same,' or 'better' revealed that, at 6 weeks, greater than 5 times the number of Usual Care patients had deteriorated (total MLHFQ) compared with the TC participants. At 12 weeks, statistically significant differences were seen in status, with TC improving in both the total MLHFQ and the physical and emotional dimensions (Table 4) .
The SF-36, the secondary quality of life outcome, included physical and mental component scales and a general health subscale (five items). A higher score indicates a better status with the SF-36 scales. Table 5 illustrates the scores at base- 
Hospital Readmission and Emergency Room Visits
The number of emergency room visits by the study group (n = 157) was calculated during the 12-week follow-up period and differed by group with significantly fewer visits being made by the TC participants. The rate of first visits was 46% in The experience in this study indicates the need for both a generic and specific HRQL outcome measure, an issue of continuing debate34-37 The condition-specific HRQL measure (MLHFQ) was more sensitive to changes in this study than the generic measure (SF-36). A possible explanation is the difficulty for individuals to separate the contribution of particular co-morbidities to perceived deficits. For instance, is the lack of mobility or ability to assume normal social roles caused by CHF or to arthritis? This trial was focused on an intervention specific to CHF care; thus, alleviation of symptoms would be more evident with a condition-specific measure.33 Theoretically, because of the nature of complex health populations having more than one prolonged condition, the use of a generic instrument is helpful in determining overall HRQL. However, the potential improvements on general quality of life with a CHF intervention in an elderly group, having more than three comorbidities, may have been diminished by the severity of their other conditions. More work on the application of condition-specific and generic HRQL instruments with complex health populations is required. However, having a generic measure aids in the comparison of those with CHF to other complex populations receiving supportive interventions. Using both instruments in this trial did not present an undue burden of administration with a fairly ill study population.
Limitations A note on generalizability of the study is pertinent. This trial was conducted in an urban center after discharge from a teaching hospital. The general medical units served a wide range of heart failure admissions including the elderly. The intervention was acceptable to most whom the pro-QUALITY OF LIFE OF INDIVIDUALS WITH HEART FAILURE gram applied (94%), and 81% completed the protocol. The length of follow-up (3 months) was comparable to other trials. The patients in the trial were ill with 77% having Stage III or IV NYHA class, and most being elderly (median 77 years). It is not known if similar results would be found with a younger, less advanced CHF population.
Further research is needed. From a health services perspective, guideline-driven interventions are an important strategy to provide evidence-based care and improve continuity. As seen in this study, the impact of such an intervention had no effect on general HRQL, yet demonstrated dramatic results on condition-specific HRQL. The next step will be in evaluating ways to tailor standard approaches to patients by considering their full range of comorbid conditions and social circumstances. Secondly, future trials of CHF hospital transition interventions should address the long-term care sector. Nearly 40% of those not eligible for this trial were from long-term care settings. Implications about outcome measurement in health service trials of reorganization of supportive care fall into two areas: (1) greater use of self-reported measure versus measures previously considered more objective, ones such as clinical endpoints or health services utilization; and (2) use of both a condition-specific and generic HRQL instrument. Ultimately, the examination of economic data in the context of self-reported, well-being data will greatly enhance our understanding of health service utilization. Lastly, components of the TC intervention, particularly the PCCHF educationalcounseling approach, should be evaluated in settings other than a teaching facility eg, primary care, community programs, and with individuals at earlier stages of heart failure.
Conclusion
In conclusion, Transitional Care has an important role to play in altering the course of patients hospitalized with heart failure. Our results suggest that with modest adjustments to usual discharge and transition from hospital-to-home, patients with CHF can experience improved quality of life, and decreased use of emergency rooms, for 3 months after hospitalization. This approach will provide the needed adjunct to current management of heart failure. It may also have application in the management of other complex medical populations associated with frequent hospital use.
